

#### **FSPFN LLL Course Topic 4 - Nutritional Support in Paediatric Patients**



FOR CLINICAL

# **Nutrition Treatment in Children** Special Emphasis on Short Bowel Syndrome



Module 4.3



Sanja Kolaček CHILDREN'S HOSPITAL ZAGREB, Croatia

01.09.2019 ESPEN LLL Programme



# DECLARATION OF CONFLICT OF INTEREST



THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM

> Received honorrarium as a lecturer / invited speaker / consultant from:

Abbott, BioGaia, Danone,

Fresenius, Nestle, Shire



# NUTRITION IN IF /SBS Lecture objectives



THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM

- Definition & aetiopathogenesis
- Clinical presentation
- Enteral / oral nutrition support (EN)
- Parenteral nutrition support (PN) & complications
- Role of surgery
- Role of team approach



NUTRITION AND METABOLISM



### CHRONIC INTESTINAL FAILURE



Reduction of gut mass/function below minimum for absorption & digestion to support life & growth Causes:

- Short Bowel Syndrome (60%-70%)
- Intractable diarrhoea congenital enteropathies (30-41%)
- Intestinal motility disorders (9%)\*\*

D'Antiga L & Goulet O. JPGN 2013; \*\* Diamanti A, et al. JPGN 2009





NUTRITION AND

METABOLISM



### SHORT BOWEL SYNDROME -SBS

Reduction of gut mass & function below minimum for absorption & digestion to support life and growth



AFTER MASSIVE SURGICAL RESECTION

**NASPGHAN DEFINITION** need for PN > 60 days after intestinal resection or a bowel length of <25% of expected

Merritt RJ et al. JPGN 2017



### SBS causes



THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM

#### Conditions leading to extensive intestinal resection

#### **PRENATAL**

Defects of abd. wall
(gastroschisis)

Apple peel syndrome

Midgut volvulus

Multiple atresias

Extensive aganglionosis

#### **NEONATAL**

Necrotising enterocolitis

Midgut volvulus

Meconium ileus

Vascular accidents

Primary motility disorders

#### **CHILDREN & ADULTS**

Vascular accidents
Invagination
Polyposis syndrome
Multiple hemangioma
Trauma, Tumours
Bypass surgery in obesity



### **IF:** how common



THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM

# IF prevalence in children (per 1000,000 <19y)

- 13.7 in UK

9.5 in the Netherland

14.1 in Italy

- 10.0 estimates for Croatia

Beath S et al. Clin Nutr 2011

Neelis EG et al. Clin Nutr 2016

Diamanti A et al. Nutrients 2017

Kolaček S. Report for HZZO 2017



# SBS: factors relevant for pathophysiology



THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND

#### **AGE**

At birth

220-250 cm of small intestine

In adults

► 400-500 cm of small intestine

#### SEGMENT OF THE BOWEL

Jejunum • leaky tight junctions ► rapid absorption, fast loss of water & Na

low ability for adaptation

**Ileum:** • specific transport for bile acids & vit B12

huge capacity for adaptation

**lleocoecal valve:**• prevents small bowel bacterial overgrowth

Colon: • conservation of water & electrolytes + extra starch digestion

#### INTEGRITY OF THE RESIDUAL INTESTINE



# Prognostic determinants of IF caused by SBS



THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM

#### **POSITIVE**

Ileum as residual segment
Ileocecal valve present
Colon in continuity
Early age at resection
"Healthy" residual GUT

#### **NEGATIVE**

Jejunum as residual segment
High jejunostomy
Resection > 1-2 y of age

Dysfunctional residual segment



# **SBS:** pathogenesis



#### THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM

#### **MAJOR DETERMINANTS**

- extent of resection
- age at resection
- type & integrity of bowel left

#### **HOW SHORT IS STILL ENOUGH?**

- <40 cm or <20%
- full blown SBS
- Life possible:
- >15-20 cm of small intestine with ileocoecal valve
- >30-40 cm of small intestine without the valve
- After adaptation:
- 100-120 cm enough for life on peroral intake (+ colon in continuity)


# ESPEN

### **INTESTINAL ADAPTATION**



THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM





Warner et al. J Pediatr Surg. 2013; 48: 20-26.



THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM



### INTESTINAL ADAPTATION



### **Hypertrophy**

- villus elongated
- crypts deeper
- mucosa ticker

Increase in absorptive surface



# Functional adjustments

- more transport proteins
- more enzymes
- slower motility





# **Control of adaptation**





### **Luminal nutrients!!!**



Saliva, bile, pancreatic secretion...





glucagon like peptide 2 – GLP2, IGF, epidermal GF, GH, insulin, polyamines...



# **SBS: Clinical presentation**



THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM

#### Early phase

(weeks after resection)

**Huge loss of** 

water and electrolytes

(jejunum vs .ileum vs. ileum + colon)

#### Intermediate phase

(months after resection)

#### Malabsorption of

nutrients & loss of

nutrients requiring

specific transport

#### Late phase

(steady state after adaptation)

# Dependence on PN complete / partial and / or special nutr. requirments and / or

#### development of complications

IFALD, loss of venous access, lithiasis, bone mineralization, D-lactacidosis...


Wales PW et al. Seminars in Pediatric Surgery 2010



### **MANAGEMENT OF SBS**







Batra A et al. Arch Dis Child Fetal Neonatol Ed 2017



# IF/SBS: major determinants of treatment



THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM

- 1. Provide nutrition to sustain life and support growth: PN+EN
- 2. Maximize intestinal adaptation
- 3. Prevent major complications of PN
  - CVC related sepsis / loss of venous access
  - IFALD (Intestinal Failure Associated Liver Disease)



### **SBS: Enteral nutrition**



#### THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND

METABOLISM

#### **ROLE**

- promotion of intestinal adaptation
- prevention of IFALD

#### RECOMMENDATION

 GUT to be used to a maximum extent but without worsening diarrhoea > avoid overfeeding!!

#### **OPTIONS???**

 breast feeding; standard formula extensivelly hydrolyzed (eHF), amino acid based (AA)

#### **MODE** ???

bolus versus continuous????

Lacaile F et al JPGN 2015

Diamanti A et al. Expert Rev Gastroenterol Hepatol 2017



# EN in SBS: type of formula





METABOLISM

#### What to recommend ??

- Only expert opinions!!
- Breast milk best option
- At start use eHF or AA, particularly in infants with dilated short segment ▶ prone to cow's milk protein allergy
- In older infants / children switch to polymeric
- Start with weaning as age appropriate

Lacaile F et al JPGN 2015

Diamanti A et al. Expert Rev Gastroenterol Hepatol 2017



METABOLISM

### EN in SBS: mode?



# **Benefits of continuous**

Better utilization of reduced surface & transport proteins

Osmotic load better tolerate

Improved growth & intestinal adaptation

# Benefits of boluses

Physiologic hormonal surge & gallblader emptying

Improved mobility & QL

Promote normal feeding, habits & skills

#### Recommendations

- Combine small boluses over day & night continuous
- Switch to boluses when appropriate

Lacaile F et al JPGN 2015 Hojsak I, Kolacek S. Liječ Vjesn 2013



### Intestinal failure: PN



THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM

1. Provide balanced iv intake

Save central veins (prevent CVC related infections)

- 3. Prevent other major complications
- IFALD (Intestinal Failure Associated Liver Disease)



NUTRITION AND

METABOLISM

### **Balanced PN**



### **Energy, amino acid solutions**

- balanced energy intake, avoid excess energy
- age adjusted composition with semi-essential amino acids arginine, cystein, taurin, proline, tyrosine

### Carbohydrate

- only glucose
- provide 70%-75% of non-protein energy
- introduce stepwise

### Lipids

- source of essential amino-aids
- provide 25% 30% of non-protein energy
- pathogenic role of quantity and quality in IFALD??

Fewtrell M et al. ESPGHAN/ESPEN/ESPR Guidelines on pediatric PN. JPGN 2018



### PATHOGENESIS OF IFALD



THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM

- Empty GUT
- Imature liver (prematurity)
- Early & recurrent sepsis
  - Intestinal stasis & bacterial overgrowth
- Lipids: quantity & quality
  - Phytosterols (from soya)

- Enteral feeding
- Balanced macro&micronutrient i.v. supply
- Cyclic PN & Home PN & Team approach
- Balanced omega 3/ omega 6 (fish oil)
  - High alphatocopherol

**Liver injury** 



**Liver protection** 

Adapted from: D'Antiga L, Goulet O. JPGN 2013



# Lipid emulsion – short term use



THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM

The use of any specific ILE for short term use in infants and children for the prevention and treatment of PNALD cannot be recommended

Hojsak I et al. ESPGHAN Committee on Nutrition Comment. JPGN 2016

	Experimental		Control		Odds Ratio		Odds Ratio
Study or Subgroup	Events		Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
5.1.1 00/S0							
Savini 00 (2013)	0	29	0	30		Not estimable	
Wang (2015)	2	50	2	50	16.4%	1.00 [0.14, 7.39]	
Subtotal (95% CI)		79		80	16.4%	1.00 [0.14, 7.39]	
Total events	2		2				
Heterogeneity: Not applica							
Test for overall effect: Z = 0.00 (P = 1.00)							
5.1.2 SMOF							
Beken (2014)	2	40	2	40	16.3%	1.00 [0.13, 7.47]	
D'Ascenzo 2.5 (2014)	1	20	1	22	7.7%	1.11 [0.06, 18.93]	
D'Ascenzo 3.5 (2014)	Ö	16	3	18	27.5%	0.13 [0.01, 2.81]	-
Savini SMOF (2013)	1	28	Ö	30	3.9%	3.33 [0.13, 85.11]	
Vlaardingerbroek (2014)	2	48	2	48	16.4%	1.00 [0.14, 7.40]	
Subtotal (95% CI)		152		158	71.8%	0.81 [0.29, 2.22]	-
Total events	6		8				
Heterogeneity: Chi <sup>2</sup> = 2.20, df = 4 (P = 0.70); i <sup>2</sup> = 0%							
Test for overall effect: Z = 0	.41 ( $P = 0.1$	68)					
5.1.3 SMF							
Savini SMF (2013)	1	27	1	30	7.8%	1.12 [0.07, 18.75]	
Subtotal (95% CI)	'	27	'	30	7.8%	1.12 [0.07, 18.75]	
Total events	1		1				
Heterogeneity: Not applica							
Test for overall effect: Z = 0.08 (P = 0.94)							
Todal of State of Sta							
5.1.4 MCT/SO							
Savini MCT (2013)	2	30	0	30	3.9%	5.35 [0.25, 116.31]	<del></del>
Subtotal (95% CI)		30		30	3.9%	5.35 [0.25, 116.31]	
Total events	2		0				
Heterogeneity: Not applica	ble						
Test for overall effect: Z = 1.07 (P = 0.29)							
							0.01 0.1 1 10 100
							Favours [experimental] Favours [control]



# PN: Pure fish oil vs fish oil in combination





Pure fish oil is effective, but as a sole source may not meet EFAs requirements on long-term basis

Emulsion with fish oil as 1 component:



- useful & safe
- possible benefit for long-term PN

ESPGHAN Committee on Nutrition JPGN 2016
Fewtrell M et al. ESPGHAN/ESPEN/ESPR Guidelines on pediatric PN. JPGN 2018



# **Type of Paediatric PN**



#### THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM

### Ready made

- cheaper, available
- not suitable for small children
   & changing requirements



- adapted to requirements of the individual child
- more appropriate for changing requirements of children with intestinal failure







# Paediatric PN in IF: prevention of common complications

THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM

Strict aseptic procedures
 on insertion & during CVC
 maintenance !!!

- Home parenteral nutrition
- Team approach

Fewtrell M et al. ESPGHAN/ESPEN/ESPR Guidelines on Pediatric PN. JPGN 2018



# Paediatric PN: compounding



THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM







# Aseptic approach: how we do it?



THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM





# HOME PARENTERAL NUTRITION







#### The best option for longterm PN !!

- better quality of life
- lower rate of CVKrelated infections
- lower costs (40% 50%)



#### For Home PN the following is required


- stable patient on cyclic PN
- structured training of caregivers
- back-up of experienced centre& nutrition support team
- availability of care 7 days/week for 24 h



# Results of intestinal Education and Culture DG Lifelong Learning Programme rehabilitation programs & TEAM



THE EUROPEAN FOR CLINICAL NUTRITION AND METABOLISM




#### Avizur Y et al. JPGN, 2015.

Single center 10y cohort from Toronto, N = 84Data compared before intruduction of intestinal rehabilitation program, first 3y with program and last 4 v.

Figure presents patient status at last follow-up

Merras-Salmio, Pakarinen. JPGN, 2015 Single center 25y experience from **Finnland** on management of SBS, N=48 At 2009 implementation of detailed protocol

Figure presents survival before and after structured team approach





# TREATMENT OF IF / SBS Education and Culture DG Lifelong Learning Programme Role of intest. rehabilitation program

THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM

"... Management of IF by Intestinal Rehabilitation Programs is current state of art, with limited, but highly encouraging, supporting data on their medical efficacy"

Merrit RJ et al. JPGN 2017

Multimodal, multidisciplinary evidence –based approach

#### involving:

- gastroenterologist, nutritionist, pharmacist, specialist nurse
- psychologist, speech therapist, physiotherapist
- surgeons



NUTRITION AND METABOLISM

# **Drug therapy**



Dehmer JJ, et al. Advances in Pediarics 2011;58

To slow transit time

loperamid

To bind bile acids

cholestiramin

To lower secretion

somatostatin

To lower acid secretion

PPI, H2 blockers

To prevent bacterial overgrowth

Trimetoprim, rifaximin metronidazol gentamycin per os......

To stimulate intestinal adaptation

GH, insulin, glutamin pectins



# SBS: Current status on GLP-2



Jeppesen PB. Curr Opin Gastroenterol 2014;30:182-8 Brubarker PL et al. Expert Opinion on Therapeutic Targets 2018 (epub)

- THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM
- 1. Increases villus height and crypt depth → higher absorption
- 2. Tends to slow-down gastric emptying & intestinal transit
- 3. In SBS patients facilitate weaning from PN



#### APPROVED BY FDA & EMA FOR PATIENTS WITH SBS-IF

#### **HOWEVE**

- 1. In some studies effect was transient
- 2. Potential to cause hyperplastic /neoplastic changes ???
- 3. Announced pricing in USA → US\$ 295 000 / patient year



#### THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND

# **SBS:** nontransplant surgery



Rege AS, et al. Nutr Clin Pract 2013, Weih S et al. Langenbecks Arch Surg 2012

- bowel lengthening (Biancchi, STEP)
- promotion of motility in dilated segment (tailoring, plication)
- slowing motility (antiperistaltic segment, valves...)
- PN-dependent patient
- time for adaptation lapsed
- deterioration of intestinal function due to dilatation & SBBO


- dilatated intestine >3 cm
- >20 cm of small intestine
- >40 cm of total bowel



### LILT – Bianchi procedure







Taken from: Sudan D. Autologous reconstruction of the GI tract. In: Langnas AN et al (eds). Intestinal failure: Diagnosis, Management and Transplantation.


Malden. Blackwell Publishing 2008; 231-41.



# Serial transverse enteroplasty - STEP



THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM



Taken from: Sudan D. Autologous reconstruction of the GI tract. In: Langnas AN et al (eds). Intestinal failure: Diagnosis, Management and Transplantation.

Malden. Blackwell Publishing 2008; 231-41.



# Intestinal transplantation When to do it?



D'Antiga L, Goulet O. JPGN 2013



### Prolonged PN versus Early transplantation (ITx)

- Prognosis after 5y, 10y: 85%, 75% for PN versus 50%, 30% for ITx
- Morbidity & mortality significantly improved in centres with multidisciplinary intestinal rehabilitation programs

#### **CURRENT RECOMMENDATIONS**


- Long-term PN is the treatment of choice for children with IF including irreversible Intestinal Failure
- IF should be treated in centres with multidisciplinary teams & intestinal rehabilitation programs
- ITx is reserved for irreversible IF with life-treatening complications:
  - loss of venous access
  - severe recurrent sepsis
  - end stage IFALD...



# MANAGEMENT OF SBS IN PAEDIATRIC PATIENTS



THE EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM



**Number of intestinal transplantations – registry** 

Grant et al. Am J Transplant. 2015 Jan;15(1):210-9.



# Nutrition Treatment of IF in children



### Conclusions



- 1. Promote appropriate nutrition
  - Enteral nutrition to the maximal extent tolerat
  - Parenteral nutrition prevent complications (age adjusted, cyclical PN, at home, aseptic approach.....)



- use GUT as early as possible & to maximum tolerated extent
- promising role of GLP-2
- role of surgical intestinal lengthening procedures
- 3. Treat in centres with multidisciplinary intestinal rehabilitation teams & programs
- 4. ITx is life saving procedure, not a routine